Page 9 of Neuren's annual report agrees with you.
"Many central nervous system (CNS) disorders exhibit common cellular and molecular pathology that manifests in a wide range of phenotypes. In particular, the role of microglia in active maintenance and support of synapses and the effect of inflammation are increasingly being recognised as central to many CNS condition. Target indications potentially addressable by Trofinetide and NNZ-2591 are summarised in the table below:"
(Source: http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01732070).
Page 9 of Neuren's annual report agrees with you. "Many central...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.38 |
Change
-0.270(1.98%) |
Mkt cap ! $1.696B | |||
| Open | High | Low | Value | Volume |
| $13.68 | $13.68 | $13.11 | $4.283M | 320.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $13.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.40 | 3328 | 3 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |